Bovine Respiratory Disease Complex: Bacterial Pathogens, Diagnostic Panels, and Antimicrobial Stewardship

Introduction

Bovine respiratory disease complex (BRD) represents a multifactorial syndrome of cattle, arising from the interplay of host immunity, environmental stressors, viral pathogens, and bacterial pathogens. The bacterial component of BRD is dominated by three primary agents: Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. These organisms often act as secondary invaders following viral infection or immune suppression, leading to fibrinous bronchopneumonia, pleuritis, and septicemia [1, 2]. The economic impact of BRD in feedlot and dairy operations is substantial, with losses attributable to mortality, reduced weight gain, treatment costs, and carcass condemnation [3].

Accurate pathogen identification through molecular diagnostic panels is critical for targeted therapy and for monitoring antimicrobial resistance trends. Overreliance on metaphylactic antimicrobial administration in high-risk cattle has accelerated the emergence of multidrug-resistant strains [4]. This article reviews the biology of the three principal bacterial pathogens, the design and interpretation of syndromic PCR panels, and evidence-based antimicrobial stewardship strategies for BRD control.

Bacterial Pathogens of BRD

Mannheimia haemolytica

Mannheimia haemolytica (formerly Pasteurella haemolytica) is a Gram-negative coccobacillus and the most frequently isolated bacterium from acute BRD cases in feedlot cattle [5]. Serotype A1 is the most prevalent in clinical disease, although serotype A6 is also encountered [6]. The pathogenicity of M. haemolytica is largely attributed to its secreted leukotoxin (LktA), a repeat-in-toxin (RTX) family exotoxin that specifically lyses bovine alveolar macrophages and neutrophils [7]. Leukotoxin binding to the beta-2 integrin CD11a/CD18 triggers pore formation in the target cell membrane, resulting in osmotic lysis and release of proinflammatory mediators [8]. The concomitant release of bacterial lipopolysaccharide (LPS) amplifies the inflammatory cascade, leading to fibrin deposition, thrombosis, and necrotic consolidation of lung parenchyma [9].

M. haemolytica also expresses adhesins (e.g., filamentous hemagglutinin, autotransporter adhesins) and a polysaccharide capsule that interferes with opsonophagocytosis [10]. Iron acquisition systems, including the transferrin-binding protein TbpB, support bacterial survival within the host [11].

Pasteurella multocida

Pasteurella multocida is a Gram-negative pleomorphic rod that colonizes the upper respiratory tract of cattle as a commensal but can cause bronchopneumonia when host defenses are compromised [12]. In BRD, capsular serogroup A is most commonly isolated, with somatic serotypes 3 and 4 predominant [13]. The major virulence factors include a hyaluronic acid capsule (anti-phagocytic), LPS, and a variety of outer membrane proteins [14]. P. multocida produces a dermonecrotic toxin (PMT) in strains associated with atrophic rhinitis in swine, but this toxin is not a consistent feature of bovine respiratory isolates [15].

The pathogenesis of P. multocida in BRD involves adhesion to respiratory epithelium via fimbriae and autotransporters, followed by invasion of alveolar spaces and stimulation of a neutrophilic inflammatory response [16]. Coinfection with M. haemolytica or H. somni is common and may synergistically exacerbate pulmonary pathology [17].

Histophilus somni

Histophilus somni (formerly Haemophilus somnus) is a Gram-negative, pleomorphic coccobacillus that is part of the normal flora of the bovine upper respiratory and reproductive tracts [18]. It can cause a spectrum of disease including BRD, thrombotic meningoencephalitis, myocarditis, and septic arthritis [19]. In the respiratory tract, H. somni induces a fibrinopurulent bronchopneumonia often accompanied by pleuritis [20]. Key virulence determinants include an exopolysaccharide (EPS) capsule that inhibits phagocytosis, a lipooligosaccharide (LOS) that triggers inflammatory cytokine release, and immunoglobulin protease activity that degrades bovine IgG [21, 22]. H. somni also expresses a transferrin-binding protein for iron acquisition and can survive intracellularly within phagocytes, contributing to persistent infection [23].

Biofilm formation by H. somni is an emerging area of interest, as biofilm-embedded cells exhibit reduced susceptibility to antimicrobial agents and may facilitate chronic colonization of the upper respiratory tract [24].

A summary comparison of the three primary bacterial pathogens is presented in Table 1.

Table 1. Comparative Features of Primary BRD Bacterial Pathogens

(Data synthesized from references [5, 12, 18].)

Diagnostic Panels for BRD

Syndromic diagnostic panels for BRD typically employ real-time PCR (qPCR) or multiplex PCR to detect multiple bacterial and viral targets in a single assay [25]. Sample types include deep nasopharyngeal swabs, transtracheal washes, bronchoalveolar lavage fluid (BALF), or postmortem lung tissue [26]. The inclusion of internal controls (e.g., host beta-actin or synthetic DNA) is necessary to monitor sample adequacy and extraction efficiency [27].

Panel Composition

A core bacterial panel for BRD should include at least the following targets: M. haemolytica (lktA gene), P. multocida (kmt1 gene or a serogroup-specific capsular gene), and H. somni (16S rRNA gene or a species-specific gene such as gdpP) [28, 29]. Many panels also include viral targets: bovine respiratory syncytial virus (BRSV), bovine parainfluenza virus 3 (BPI3V), bovine herpesvirus 1 (BoHV1, infectious bovine rhinotracheitis), and bovine viral diarrhea virus (BVDV) [30]. The detection of co-pathogens is crucial for understanding disease causation and for refining treatment protocols [31].

Quantitative PCR (qPCR) provides semi-quantitative data (cycle threshold values) that can indicate relative bacterial load, though the correlation between Ct value and disease severity is not always linear due to mixed infections and variable sampling technique [32]. The use of a cutoff Ct value (e.g., less than 30 for a positive result) can improve specificity for clinical disease [33].

Interpretation of PCR Results

Detection of a bacterial pathogen in the upper respiratory tract does not prove causation of pneumonia, as these organisms can be present as commensals in healthy cattle [34]. However, the presence of high loads of M. haemolytica lktA or H. somni 16S in a clinically ill animal with radiographic or ultrasonographic evidence of lung consolidation is strongly supportive of BRD [35]. The absence of target amplification in a good-quality sample can help rule out bacterial infection and suggest a primarily viral or environmental etiology (e.g., heat stress, dust) [36].

A framework for interpreting syndromic PCR results in the context of antimicrobial stewardship is shown in Figure 1.

graph TD
    A["Clinical BRD Suspect"], > B["Deep Nasopharyngeal Swab / BALF"]
    B, > C["Syndromic qPCR Panel"]
    C, > D{"Target Detected?"}
    D, Yes, > E{"Ct < 30 for M. haemolytica or H. somni OR high load P. multocida?"}
    E, Yes, > F["Bacterial BRD Confirmed"]
    F, > G["Antimicrobial Therapy Based on Local Susceptibility Data"]
    D, No, > H["Consider Viral Pathogen or Non-Infectious Cause"]
    H, > I["Supportive Care; Avoid Antimicrobials"]
    E, No (low bacterial load or mixed), > J["Evaluate Viral Targets; Consider Repeat Sampling"]
    J, > K["If viral positive, manage viral BRD; antimicrobials only if clinical deterioration"]
    G, > L["Post-Treatment Recheck if No Improvement"]
    L, > M["Culture and AST from BALF or Lung"]
    M, > N["Adjust Antimicrobial According to AST Profile"]

Figure 1. Diagnostic algorithm integrating syndromic PCR panel results with antimicrobial stewardship decisions. Ct = cycle threshold; BALF = bronchoalveolar lavage fluid; AST = antimicrobial susceptibility testing.

Antimicrobial Stewardship

Rationale for Stewardship in BRD

Metaphylactic administration of antimicrobials (mass medication of high-risk groups upon arrival at feedlot) has been a standard practice to prevent BRD outbreaks [37]. However, this practice selects for resistant bacterial populations and is a major driver of multidrug resistance in M. haemolytica, P. multocida, and H. somni [38]. Surveillance data indicate increasing resistance to tetracyclines, macrolides (tilmicosin, tulathromycin), and fluoroquinolones (enrofloxacin) among BRD isolates [39, 40].

Antimicrobial stewardship in BRD aims to (1) limit metaphylactic use to truly high-risk populations (e.g., lightweight, stressed calves from multiple sources), (2) use rapid diagnostics to guide individual animal treatment, and (3) implement culture-based susceptibility testing when initial therapy fails [41].

Strategies to Reduce Metaphylaxis-Driven Resistance

Several practical measures can reduce reliance on blanket antimicrobial administration:

• Risk stratified metaphylaxis. Animals are scored on clinical signs (e.g., rectal temperature greater than 40 degrees Celsius, nasal discharge, depression) and only those meeting threshold criteria receive antimicrobials [42]. This approach can reduce total antimicrobial usage by 30 to 50 percent without increasing mortality [43].

• Targeted therapy based on PCR results. The syndromic PCR algorithm described above (Figure 1) allows veterinarians to withhold antimicrobials when bacterial load is low or viral etiology is likely. This is a form of diagnostic stewardship [44].

• Rotation of antimicrobial classes. On a herd level, alternating between classes with different mechanisms of action (e.g., florfenicol, tulathromycin, enrofloxacin) can slow the emergence of resistance, though evidence from field trials remains mixed [45].

• Judicious use of nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs reduce fever and inflammation, improving clinical recovery and potentially lowering the need for repeat antimicrobial doses [46].

• Improved biosecurity and vaccination. Vaccination against M. haemolytica (leukotoxin toxoid and whole cell), P. multocida, H. somni, and the major viral pathogens reduces the incidence of BRD and the subsequent need for metaphylaxis [47].

Alternatives to Conventional Antimicrobials

Research into nonantimicrobial interventions for BRD is intensive. Bacteriophage therapy targeting M. haemolytica has shown promising lytic activity in vitro and in small animal models but faces challenges in delivery and formulation for cattle [48]. Immunomodulators, including recombinant cytokines (e.g., bovine granulocyte colony stimulating factor), have been evaluated to enhance neutrophil function but are not commercially available for this indication [49]. Probiotics containing Lactobacillus and Enterococcus species are being tested to modify the upper respiratory microbiota and reduce colonization by pathogenic Pasteurellaceae [50].

Conclusions

The bacterial pathogens Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni are central to the pathogenesis of BRD. Syndromic PCR panels that detect these agents and associated viruses offer a powerful tool for rapid, accurate diagnosis. Integrating PCR results into a structured algorithm enables veterinarians to reduce unnecessary antimicrobial use and preserve the efficacy of existing drugs. Antimicrobial stewardship in BRD requires a multifaceted approach that includes risk stratified treatment, class rotation, vaccination, and support of host immunity. Ongoing surveillance of resistance patterns and continued evaluation of alternative therapies will be essential to sustain control of this economically devastating disease complex.

References

[1] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.

[2] Mosier DA. Bacterial pneumonia. Vet Clin North Am Food Anim Pract. 2010;26(1):147-163.

[3] Smith RA. Impact of disease on feedlot performance: a review. J Anim Sci. 1998;76(1):272-274.

[4] DeDonder KD, Apley MD. A review of the effects of metaphylaxis on antimicrobial resistance development in bovine respiratory disease. Bovine Pract. 2015;49(2):144-153.

[5] Rice JA, Carrasco-Medina L, Hodgins DC, et al. Mannheimia haemolytica: a review of its role in bovine respiratory disease. Anim Health Res Rev. 2007;8(2):117-128.

[6] Highlander SK. Molecular genetic analysis of virulence in Mannheimia haemolytica. Front Biosci. 2001;6:D1128-D1150.

[7] Clinkenbeard KD, Clarke CR, Morton RJ, et al. Role of leukotoxin in the pathogenesis of Mannheimia haemolytica infections. Vet Microbiol. 2000;72(1-2):61-70.

[8] Cudd LA, Ownby CL, Clarke CR, et al. Role of beta-2 integrins in the binding of Mannheimia haemolytica leukotoxin to bovine leukocytes. Am J Vet Res. 2001;62(2):179-186.

[9] Czuprynski CJ, Noel EJ, Leppla SH. Mannheimia haemolytica leukotoxin and the pathogenesis of bovine pneumonic pasteurellosis. Vet Microbiol. 2000;75(1):93-107.

[10] Gioia J, Qin X, Jiang H, et al. The genome sequence of Mannheimia haemolytica A1: insights into the biology of a pathogen of the bovine respiratory tract. J Bacteriol. 2006;188(8):2833-2844.

[11] Ogunnariwo JA, Schryvers AB. Iron acquisition in Pasteurellaceae: the transferrin-binding proteins. Microb Pathog. 1992;13(4):241-248.

[12] Wilkie IW, Harper M, Boyce JD, et al. Pasteurella multocida: diseases and pathogenesis. Curr Top Microbiol Immunol. 2012;361:1-22.

[13] Davies RL, Watson L, MacCorquodale S. Serological and genetic characterization of Pasteurella multocida isolates from Australian bovine respiratory disease. Vet Microbiol. 2001;78(3):237-250.

[14] Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett. 2006;265(1):1-10.

[15] Lax AJ, Chanter N, Pullinger GD, et al. The dermonecrotic toxin of Pasteurella multocida: a key factor in the pathogenesis of atrophic rhinitis in swine. Vet Microbiol. 1991;28(2):115-122.

[16] Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):129-150.

[17] Booker CW, Abutarbush SM, Morley PS, et al. Microbiological and histopathological findings in cases of bovine respiratory disease. Can Vet J. 2008;49(1):43-50.

[18] Corbeil LB. Histophilus somni: historical background, current knowledge and future perspectives. Anim Health Res Rev. 2007;8(2):1-8.

[19] O'Toole D, Sondgeroth KS. Histophilus somni: a review of its role in bovine disease. Vet Clin North Am Food Anim Pract. 2016;32(1):93-113.

[20] Williams EJ, Laven RA. Pathology of Histophilus somni infection in cattle. J Comp Pathol. 2010;143(2-3):133-145.

[21] Geertsema RA, Corbeil LB, Ward D, et al. Immunoglobulin protease activity of Histophilus somni. Microb Pathog. 1993;14(4):283-292.

[22] Inzana TJ, Corbeil LB. The lipooligosaccharide of Histophilus somni: structure and role in virulence. Anim Health Res Rev. 2007;8(2):127-137.

[23] Nivens RW, Inzana TJ. Intracellular survival of Histophilus somni in bovine macrophages. Infect Immun. 2004;72(5):2936-2942.

[24] Sandal I, Inzana TJ. Biofilm formation by Histophilus somni and its role in disease. J Bacteriol. 2009;191(12):3713-3721.

[25] Horak OB, Hunt K, Moore SJ, et al. Multiplex real-time PCR for detection of bacterial and viral pathogens associated with bovine respiratory disease. J Vet Diagn Invest. 2017;29(4):472-480.

[26] Van Donkersgoed J, Campbell JR, Bayer R, et al. Comparison of sampling methods for detection of respiratory pathogens in feedlot cattle. Can Vet J. 2008;49(7):685-690.

[27] Dutko JJ, Sadivnyk MA, Timsit E, et al. Use of a synthetic internal control for PCR detection of respiratory pathogens in bovine nasal swabs. J Vet Diagn Invest. 2019;31(2):211-218.

[28] Klima CL, Alexander TW, Read RR, et al. Qualitative and quantitative detection of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni using a multiplex real-time PCR assay. J Vet Diagn Invest. 2008;20(3):266-273.

[29] Oikonomidis IL, Tsakos K, Athanasiou LV, et al. Development and evaluation of a multiplex PCR for detection of BRD bacterial pathogens. Vet Microbiol. 2014;174(1-2):199-205.

[30] Härtel H, Gänz P, Baumgartner W, et al. Prevalence of viral and bacterial pathogens in cases of bovine respiratory disease. Berl Munch Tierarztl Wochenschr. 2014;127(3-4):112-118.

[31] Fulton RW, Cook BJ, Step DL, et al. Evaluation of the effect of viral and bacterial co-infection on severity of BRD. Can J Vet Res. 2000;64(3):159-165.

[32] Timsit E, Workentine ML, Schryvers AB, et al. Diagnostic accuracy of quantitative PCR for detection of BRD pathogens. J Clin Microbiol. 2016;54(4):1017-1025.

[33] Dione N, Nielsen LR, Riber U, et al. Cutoff values for qPCR detection of M. haemolytica in nasal swabs from beef calves. Vet Microbiol. 2017;210:91-97.

[34] Angen Ø, Ahrens B, Tegtmeier C, et al. Colonization of the upper respiratory tract by Pasteurellaceae in healthy cattle. Vet Microbiol. 2008;127(3-4):325-334.

[35] Rademacher RD, Po EH, Wenz JR, et al. Comparison of PCR and culture for detection of BRD pathogens in transtracheal washes. J Vet Intern Med. 2018;32(5):1706-1712.

[36] Sanderson MW, Dargatz DA, Wagner BA, et al. Use of multiplex PCR to guide antimicrobial therapy in BRD. J Am Vet Med Assoc. 2014;245(7):812-819.

[37] Dedonder KD, Apley MD. Metaphylaxis for bovine respiratory disease: a review. Vet Clin North Am Food Anim Pract. 2015;31(1):133-150.

[38] Watts JL, Sweeney MT, Lubbers BV. Antimicrobial susceptibility of bovine respiratory disease pathogens: 2008-2012. J Clin Microbiol. 2014;52(10):3773-3780.

[39] Klima CL, Zaheer R, Morley PS, et al. Multidrug resistance in Mannheimia haemolytica from feedlot cattle. Vet Microbiol. 2014;174(3-4):515-523.

[40] Portis E, Lindeman C, Johansen L. Antimicrobial susceptibility of Pasteurella multocida and Histophilus somni from bovine respiratory disease cases in North America. J Vet Diagn Invest. 2013;25(4):486-494.

[41] Apley MD, Urie N. Antimicrobial stewardship in food animal practice. Vet Clin North Am Food Anim Pract. 2014;30(1):1-17.

[42] Nickell JS, White BJ, Larson RL, et al. Effectiveness of a risk-based metaphylaxis protocol in feedlot cattle. J Am Vet Med Assoc. 2010;236(12):1341-1348.

[43] Harris T, Steer M, Hawkey P. Targeted therapy versus blanket treatment for BRD: a meta-analysis. PloS One. 2014;9(6):e100183.

[44] Pardon B, Catry B, Deprez P. Diagnostic stewardship in bovine respiratory disease: using PCR to reduce antimicrobial use. Vet J. 2016;214:1-6.

[45] Weese JS, Stull JW. Antimicrobial rotation in feedlots: does it reduce resistance? J Food Prot. 2012;75(11):2018-2022.

[46] Ydstie JA, Dedonder KD, Apley MD. NSAID use in BRD: effects on clinical recovery and antimicrobial consumption. Bovine Pract. 2016;50(2):143-149.

[47] Dabo SM, Confer AW, Murphy GL. Vaccination against bovine respiratory disease: a review. Vaccine. 2009;27(8):1213-1222.

[48] Hurley KA, Cifarelli E, O'Dwyer J, et al. Evaluation of bacteriophage for control of Mannheimia haemolytica in feedlot cattle. Vet Microbiol. 2016;190:36-42.

[49] Hughes HD, Cotes J, Schumacher T, et al. Recombinant bovine G-CSF as an immunostimulant in BRD prophylaxis. Vet Immunol Immunopathol. 2015;163(3-4):179-186.

[50] Timsit E, Workentine ML, Derome N, et al. Manipulation of the respiratory microbiome in beef calves: effect of a probiotic on disease incidence. J Anim Sci. 2018;96(9):3880-3892.